StockIQ.techTakeda Pharmaceutical Company Limited (4502.T) Stock Analysis
Free AI-powered analysis and research for Takeda Pharmaceutical Company Limited stock
Sector: Healthcare
4502.T snapshot
Data as of 2 Nov 2026 close. Updated daily.
Takeda Pharmaceutical Company Limited scores 58/100 on StockIQ's model, which reads as mixed signals overall. The price is above its 200-day average and at 94% of its 52-week range, up 58.4% over the past year. Latest reported figures show a profit margin of -3.5%, return on equity of -2.3% and revenue growth of +10.2%.
What is driving the score
- Strong Uptrend: +12
- MACD Bullish: +8
- Unprofitable (-3.5%): -15
- Weak Liquidity (1.14 Current Ratio): -5
- Negative ROE (-2.3%): -10
- Strong Long-term Uptrend: +8
- Strong Rise (+58.4% over 1 year): +10
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full 4502.T report
Takeda Pharmaceutical Company Limited (4502.T) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze 4502.T Now →📰 Latest Update
What Takeda Pharmaceutical (TAK) Said on Its Q2 Earnings Call
Fri, October 30, 2026 at 11:14 AM UTC 4 min read
Takeda Pharmaceutical (4502.T) reported strong Q2 earnings, driven by robust sales in its core therapeutic areas, particularly oncology and rare diseases. The company raised its full-year guidance, reflecting confidence in its product pipeline and market demand. For investors, this positive outlook signals potential for continued growth and stability, making Takeda an attractive option in the pharmaceutical sector.